Botanix Pharmaceuticals runs clinical studies of its synthetic cannabinoid development products in Australia, New Zealand the USA. We are currently recruiting healthy volunteers (adults) to participate in a research study for our BTX 1801 antimicrobial product in Perth, Western Australia.
The aim of the study is to eradicate Staphylococcus aureus including methicillin-resistant Staphylococcus aureus (‘MRSA’) from the nose of individuals known to carry the bacterium in their nasal cavity. Nasal carriage of Staphylococcus aureus greatly increases the risks of serious and sometimes life-threatening infections following surgery.
The study will enrol 60 volunteers, but will screen a pool of at least 180 volunteers for nasal carriage of Staphylococcus aureus, as approximately one in three people carry the bacterium in their nose.
To learn more about the qualifying criteria for this study and to register your interest, please complete this form.